Literature DB >> 21771576

Design and reshaping of an scFv directed against human platelet glycoprotein VI with diagnostic potential.

Muhammad Zahid1, Stéphane Loyau, Maxime Bouabdelli, Nicolas Aubrey, Martine Jandrot-Perrus, Philippe Billiald.   

Abstract

Blood platelets play a key role in physiological hemostasis and in thrombosis. As a consequence, platelet functional analysis is widely used in the diagnosis of hemorrhagic disorders as well as in the evaluation of thrombosis risks and of the efficacy of antithrombotics. Glycoprotein (GP) VI is a platelet-specific collagen-signaling receptor. Clinical studies suggest that increased GPVI expression is associated with a risk of arterial thrombosis. Conversely, GPVI deficiencies have been identified in patients with defective platelet responses to collagen. Currently, there is no standard test available for measuring GPVI expression, essentially because antibodies usually cross-link GPVI upon binding, leading to platelet activation and consecutive changes in GPVI expression. Here, we designed a recombinant monovalent antibody fragment (scFv) derived from an anti-GPVI monoclonal IgG, 3J24, with the characteristics required to analyze GPVI expression. Guided by in silico modeling and V-KAPPA chain analysis, a Protein L (PpL) recognition pattern was engineered in the scFv, making possible its purification and detection using PpL conjugates. The PpL affinity-purified scFv is functional. It retains GPVI-binding specificity and allows detection of platelet surface-expressed GPVI without inducing platelet activation. In conclusion, the reshaped scFv may be very useful in the development of diagnostic approaches.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771576     DOI: 10.1016/j.ab.2011.06.036

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies.

Authors:  Conor Fields; David O'Connell; Sujing Xiao; Gil U Lee; Philippe Billiald; Julien Muzard
Journal:  Nat Protoc       Date:  2013-05-16       Impact factor: 13.491

2.  Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan.

Authors:  Peng Jiang; Stéphane Loyau; Maria Tchitchinadze; Jacques Ropers; Guillaume Jondeau; Martine Jandrot-Perrus
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

3.  A method to confer Protein L binding ability to any antibody fragment.

Authors:  Zineb Lakhrif; Martine Pugnière; Corinne Henriquet; Anne di Tommaso; Isabelle Dimier-Poisson; Philippe Billiald; Matthieu O Juste; Nicolas Aubrey
Journal:  MAbs       Date:  2015-12-18       Impact factor: 5.857

4.  Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences.

Authors:  Thomas Cnudde; Zineb Lakhrif; Justine Bourgoin; Fanny Boursin; Catherine Horiot; Corinne Henriquet; Anne di Tommaso; Matthieu Olivier Juste; Isabella Gizzi Jiacomini; Isabelle Dimier-Poisson; Martine Pugnière; Marie-Nöelle Mévélec; Nicolas Aubrey
Journal:  Antibodies (Basel)       Date:  2020-04-15

Review 5.  Targeting GPVI as a novel antithrombotic strategy.

Authors:  Robert K Andrews; Jane F Arthur; Elizabeth E Gardiner
Journal:  J Blood Med       Date:  2014-05-21

6.  Proteolytic processing of platelet receptors.

Authors:  Elizabeth E Gardiner
Journal:  Res Pract Thromb Haemost       Date:  2018-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.